Loading
A phase 1/2 trial of PTT-936 in advanced solid tumours, run by Pyrotech Therapeutics, Inc., now recruiting.
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06244992 by Pyrotech Therapeutics, Inc., with 68 participants planned, started 2024-01-26 and due to reach its primary completion in 2027-09-30. Interventions recorded: PTT-936 and Combination of PTT-936 and anti-PD-1/L1 therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/